Jeff Evanson - 20 Mar 2024 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Reporting relationship: CHIEF COMMERCIAL OFFICER
Issuer ticker: OTLK
Reported as of: 20 Mar 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Mar 2024, 17:00:24 UTC
Prior SEC filing: 11 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Lawrence Kenyon, Attorney-in-Fact

Key filing fact

Jeff Evanson filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 22 Mar 2024.

Key facts

This page summarizes Jeff Evanson's Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Mar 2024, 17:00.

Change

Previous filing in this sequence was filed on 11 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OTLK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 20 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $6.78
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option shall vest on March 20, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.